<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082053</url>
  </required_header>
  <id_info>
    <org_study_id>ASLAN001-010</org_study_id>
    <nct_id>NCT03082053</nct_id>
  </id_info>
  <brief_title>A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours</brief_title>
  <official_title>A Phase Ib Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aslan Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aslan Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore safety and efficacy of varlitinib administered as
      monotherapy in Japanese subjects with advanced or metastatic solid tumors, and administered
      as combination with capecitabine in Japanese subjects with advanced or metastatic biliary
      tract cancer. Also to evaluate pharmacokinetics (PK) of varlitinib, capecitabine and its
      metabolite.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 31, 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Actual">December 7, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>2 studies of single group in 1 protocol</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients with a dose limiting toxicity (DLT) in the first treatment cycle</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) or Recommended Phase II Dose (RP2D) in Phase I setting.</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: varlinitib, capecitabine and 5-FU metabolites levels in terms of Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Through, Day 1, Day 3, Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: varlinitib, capecitabine and 5-FU metabolites levels in terms of Area under the plasma concentration-time curve (AUC) from 0 to 12 hours (AUC0-12)</measure>
    <time_frame>Through, Day 1, Day 3, Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: varlinitib, capecitabine and 5-FU metabolites levels in terms of Minimum (trough) plasma concentration (Cmin)</measure>
    <time_frame>Through, Day 1, Day 3, Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: varlinitib, capecitabine and 5-FU metabolites levels in terms of Elimination half-life of Phase β (t1/2β)</measure>
    <time_frame>Through, Day 1, Day 3, Day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Advanced or Metastatic Biliary Tract Cancer</condition>
  <condition>Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Study I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varlitinib given as monotherapy to Japanese subjects with advanced or metastatic solid tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varlitinib given in combination with capecitabine to Japanese subjects with advanced or metastatic biliary tract cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varlitinib</intervention_name>
    <description>IMP</description>
    <arm_group_label>Study I</arm_group_label>
    <arm_group_label>Study II</arm_group_label>
    <other_name>ASLAN001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Companion Medication</description>
    <arm_group_label>Study II</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study I: Subjects with a solid tumour (excluding haematologic tumors) in advanced or
             metastatic stage

          -  Study II: Subjects with advanced (unresectable) or metastatic biliary tract cancer
             (IHCC, EHCC, gallbladder cancer or ampullary carcinoma)

        Exclusion Criteria:

          -  Subjects with concurrent multiple primary cancers.

          -  Subjects with a history of (non-infectious) pneumonitis that required steroids or
             current pneumonitis, or with a history of interstitial lung disease or current
             interstitial lung disease

          -  Subjects receiving proton pump inhibitors for established, symptomatic gastro-duodenal
             ulceration or gastroesophageal reflux disease (including the preventive use)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ASLAN Selected sites</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

